Stereotaxis (STXS)
:STXS
Want to see STXS full AI Analyst Report?
STXS Stock Chart & Stats
$2.03
-$0.10(-4.18%)
At close: 4:00 PM EST
$2.03
-$0.10(-4.18%)
Day’s Range― - ―
52-Week Range$1.70 - $3.59
Previous CloseN/A
Volume282.58K
Average Volume (3M)583.61K
Market Cap
$176.90M
Enterprise Value$184.18M
Total Cash (Recent Filing)$14.62M
Total Debt (Recent Filing)$5.28M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding97,736,700
10 Day Avg. Volume380,338
30 Day Avg. Volume583,610
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue5.90
Enterprise Value/Gross Profit10.96
Enterprise Value/Ebitda-9.43
Forecast
1Y Price Target
$4.13Price Target Upside103.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$39.40M
Bulls Say, Bears Say
Bulls Say
Regulatory Approvals Expanding Addressable MarketMultiple recent FDA approvals (PMA for MAGIC, clearance for Synchrony, Genesys X clearance and approvals in Europe/China) establish a regulatory foundation for a broader product ecosystem. This durable credential reduces regulatory tail risk, opens new geographies and use-cases, and materially expands long-term commercial opportunity for capital and consumable sales.
High Product-level Gross MarginsStereotaxis' reported 60% overall gross margin and 66% recurring margin indicate strong product-level economics. These margins provide durable upside as higher-margin recurring and disposable revenue scales, enabling operating leverage and making margin expansion feasible even before full capital-sale conversion.
Material Disposable Revenue Per ProcedureEarly MAGIC catheter procedures generate high per-procedure disposable revenue, often above $8k. This creates a recurring, razor-blade revenue stream tied to procedure volume and installed base growth. If manufacturing ramp and adoption proceed, disposables can sustainably drive revenue and margin improvement over the medium term.
Bears Say
Sustained Negative Free Cash FlowLarge negative operating and free cash flow is a durable structural risk: ongoing cash burn requires external financing or rapid operational improvement. Until recurring disposable revenue materially scales, the firm faces funding pressure which can force dilution, constrain investments, or slow commercialization over the next several quarters.
Very Large Operating Losses And Negative ReturnsTTM EBIT and net margins near -70% show the company is consuming capital rather than compounding it. Persistent deep losses erode equity, limit reinvestment capacity, and make the path to sustainable profitability highly execution-dependent on capital sales ramp and disposable monetization.
Manufacturing And Transition Execution RiskCapacity constraints and a messy transition from a legacy J&J supply relationship have constrained procedure volumes and revenue recognition. Meeting the target of ~500 catheters/month is critical; failure to scale manufacturing or smooth supplier transitions would delay disposable revenue, slowing margin improvement and commercial adoption.
Stereotaxis News
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $1.70 and its highest was $3.59 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $176.90M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is Aug 11, 2026 which is in 61 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on May 12, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.01.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.05.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 97,736,700 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.646%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stereotaxis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.13 (103.20% Upside)
$4.13 (103.20% Upside)
Hedge Fund Trend
Increased
By 126.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.85%
12-Months-Change
Fundamentals
Return on Equity
-153.21%
Trailing 12-Months
Asset Growth
18.21%
Trailing 12-Months
Company Description
Stereotaxis
Stereotaxis, Inc. specializes in the development, manufacturing, and commercialization of robotic systems, specialized instruments, and information management solutions for interventional laboratories, serving both domestic and international markets. A cornerstone of their product portfolio is their robotic magnetic navigation (RMN) technology, embodied by the Genesis RMN and Niobe systems. These innovative platforms empower clinicians to perform intricate interventional procedures by precisely guiding catheters and guidewires, under image guidance, through the vasculature and heart chambers to specific treatment sites. The company further delivers Odyssey, an advanced real-time information system designed to facilitate the management, control, recording, and secure sharing of procedural data across various networks. For robotic interventional operating rooms, Stereotaxis offers the Imaging Model S X-ray system, a comprehensive single-plane X-ray unit complete with a c-arm, powered table, motorized boom, and high-definition monitors. Complementing its primary systems, Stereotaxis provides a range of disposable components and accessories. This includes QuikCAS, which enables automated, remote advancement of electrophysiology catheters, as well as various steerable tip diagnostic and ablation catheters like the CARTO RMT, CELSIUS RMT, and several NAVISTAR RMT models, some featuring irrigated tips. Additionally, they offer Vdrive, a system engineered to enhance the navigation and stability of diagnostic and therapeutic devices during interventional procedures, alongside disposable elements such as V-Loop, V-Sono, and V-CAS. Stereotaxis distributes its offerings through a combination of its dedicated direct sales force, distributors, and sales agents. The company has also forged a strategic alliance with Osypka AG to jointly develop a magnetic ablation catheter leveraging Stereotaxis' proprietary robotic technology. Founded in 1990, Stereotaxis, Inc. maintains its headquarters in Saint Louis, Missouri.
STXS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced transformational strategic progress with near-term execution and financial headwinds. Major positives include multiple recent FDA approvals (MAGIC, Synchrony), successful early clinical use of the MAGIC catheter, a clear disposable revenue opportunity (disposables often >$5k–$8k per procedure), Genesys X and Synchrony commercialization steps, and the Robocath acquisition that strengthens long-term robotics strategy. Offsetting these are short-term declines in reported revenue (Q1 revenue down ~16%), capacity constraints and supply transition issues due to winding down the Johnson & Johnson relationship, continued operating losses, and increasing negative free cash flow. Management reiterated >$40M revenue guidance for 2026 and described a path to ramp and profitability, but achieving that depends on manufacturing ramp, adoption of disposables, and execution of capital sales.View all STXS earnings summariesSTXS Stock 12 Month Forecast
Average Price Target
$4.13
▲(103.20% Upside)
Technical Analysis
Atricure
―
Lemaitre Vascular
―
Merit Medical Systems
―
Staar Surgical
―
Milestone Scientific
―
Ownership Overview
20.54% Insiders
6.47% Mutual Funds
28.40% Other Institutional Investors
39.05% Public Companies and
Individual Investors